Latest NewsView all news
Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clinical Development, Regulatory and Commercial Milestones, Plus Commercial Royalties
Sign up today and receive company updates straight to your inbox.
Kiora Pharmaceuticals, Inc.
332 Encinitas Boulevard
Encinitas, CA 92024